MannKind

MannKind

Yahoo Finance • 4 days ago

Intel, Amkor on AI optimism; eBay slips

Investing.com - U.S. stock futures edged higher on Friday, recovering after a broad selloff in the previous session as investors weighed persistent geopolitical tensions in the Middle East against another wave of upbeat corporate earnings... Full story

Yahoo Finance • 4 days ago

MannKind Announces $50 Million Private Placement

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 24, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions... Full story

Yahoo Finance • 8 days ago

What This MannKind Sale Signals With Tyvaso Royalties at $32.7 Million

Key Points David Thomson disposed of 123,000 shares at $4.08 per share, representing a total transaction value of about $500,000. The activity resulted in a 13% decrease in direct common stock holdings, which included shares recently acqu... Full story

Yahoo Finance • 8 days ago

Why This MannKind Insider Stock Sale Matters Less Than a 9% Royalty at Risk

Key Points This filing reported an insider's total disposition of 65,808 shares for an estimated value of $269,000 based on the July 15, 2026 market close. The transaction represented 6% of the insider's total direct common stock holdings... Full story

Yahoo Finance • 19 days ago

MannKind Corporation (MNKD) Up 20% Since Afrezza FDA Approval

MannKind Corporation (NASDAQ:MNKD) is one of the Best Penny Stocks to Invest In According to Billionaires. MannKind Corporation (NASDAQ:MNKD) has gained roughly 20% since the FDA approved Afrezza, which is an inhaled insulin for children a... Full story

Yahoo Finance • 29 days ago

Is MannKind Corporation (MNKD) A Good Stock To Buy Now?

Is MNKD a good stock to buy? We came across a bullish thesis on MannKind Corporation on BioEquity Watch's Substack. In this article, we will summarize the bulls' thesis on MNKD. MannKind Corporation's share was trading at $3.8400 as of Jun... Full story

Yahoo Finance • last month

Wells Fargo Calls MannKind Corporation (MNKD)’s Commercial Potential a “Show-Me Story”

MannKind Corporation (NASDAQ:MNKD) is among the hidden penny stocks to invest in. On June 1, Wells Fargo lifted the price target on MannKind Corporation (NASDAQ:MNKD) to $11 from $10 and reiterated an Overweight rating. The firm associated... Full story

Yahoo Finance • 2 months ago

Mankind: Afreezza Data At ADA 2026 Underscores Pediatric Safety And Expands Use In Diabetes Care

(RTTNews) - MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company focused on chronic disease care, presented new clinical and real-world findings on Afrezza (inhaled insulin) at the American Diabetes Association's 2026 Scientifi... Full story

Yahoo Finance • 2 months ago

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems

Builds on recent FDA approval (May 29, 2026) of Afrezza for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetesNew data and real-world findings further emphasize pediatric safety, glycemic control and tr... Full story

Yahoo Finance • 2 months ago

MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that management will host a conference call to discuss the recent FDA approval of Afrezza® for use in child... Full story

Yahoo Finance • 2 months ago

MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes

Enables dosing at the start of a meal, offering flexibility for children and adolescents as they manage school, sports, meals, and snacks throughout the dayApproval advances pediatric diabetes care by introducing a new inhaled mealtime ins... Full story

Yahoo Finance • 3 months ago

H.C. Wainwright and Wells Fargo Lift MannKind (MNKD) Price Targets

MannKind Corporation (NASDAQ:MNKD) is one of the 10 Best US Stocks Under $5 to Buy. On May 7, H.C. Wainwright increased its price target on MannKind Corporation (NASDAQ:MNKD) from $8 to $10 and kept its Buy rating on the stock. The resear... Full story

Yahoo Finance • 3 months ago

How The MannKind (MNKD) Story Is Shifting With Tyvaso DPI And Soft Mist Uncertainty

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. MannKind’s fair value estimate has been trimmed from US$7.50 to ab... Full story

Yahoo Finance • 3 months ago

Why MannKind Corporation (MNKD) is One of the Best Stocks Under $5 With Huge Upside Potential

MannKind Corporation (NASDAQ:MNKD) is one of the best stocks under $5 with huge upside potential. Mizuho cut the price target on MannKind Corporation (NASDAQ:MNKD) to $8 from $10 on April 13 and reaffirmed an Outperform rating on the share... Full story

Yahoo Finance • 3 months ago

Truist Securities Touts MannKind Corporation (MNKD) Prospects on Tyvaso Franchise Development

MannKind Corporation (NASDAQ:MNKD) is one of the best healthcare penny stocks to buy according to hedge funds. On March 30, Truist Securities reiterated that MannKind (NASDAQ:MNKD) is a Buy with a $7 price target in response to positive tr... Full story

Yahoo Finance • 3 months ago

10 high-profitability small-cap stocks with lowest YTD performance in 2026

[Man looking at currency trading app on his smart phone from his home office] Alistair Berg A notable shift is underway in the small-cap market in 2026: profitable Russell 2000 companies are decisively outperforming their non-profitable c... Full story

Yahoo Finance • 4 months ago

Clinical Nutrition for Diabetes Care Market Report 2026-2030 Featuring Profiles of Key Players - Pfizer, Bayer, Sanofi-Aventis, Abbott Labs, Roche and More

Company Logo The rise of diabetes, demand for specialized nutrition, digital monitoring tools, and home-based management are key trends driving market growth Clinical Nutrition for Diabetes Care MarketClinical Nutrition for Diabetes Care... Full story

Yahoo Finance • 5 months ago

MannKind Corporation (MNKD) Outlines Expansion Plans and Revenue Targets

MannKind Corporation (NASDAQ:MNKD) is among the best NASDAQ penny stocks to buy according to analysts. On 26 February, MannKind Corporation (NASDAQ:MNKD) shared its plans at the Oppenheimer healthcare conference. The company said it expect... Full story

Yahoo Finance • 5 months ago

MannKind Corporation (MNKD): A Bull Case Theory

We came across a bullish thesis on MannKind Corporation on X.com by @MoneyShow. In this article, we will summarize the bulls’ thesis on MNKD. MannKind Corporation's share was trading at $3.5000 as of February 25th. MNKD’s trailing and forw... Full story

Yahoo Finance • 7 months ago

Is MannKind Stock a Buy or Sell After the CEO Sold Nearly 66,000 Shares?

Key Points CEO Michael Castagna sold 65,804 shares on Dec. 17, 2025, for a total value of approximately ~$395,482 at a weighted average price around $6.01 per share. This transaction represented 2.56% of Mr. Castagna's direct holdings, re... Full story